Merck completed the acquisition of HUB Organoids.

Merck, a global pharmaceutical and chemical company, completed the acquisition HUB Organoids, an adult stem cell-derived organoids developer. Financial terms were not disclosed. “The use of organoids offers tremendous potential to improve the drug discovery process. HUB’s advanced technology, combined with our innovations in 3D cell culture and broad portfolio, makes us a valuable resource for researchers looking to leverage the power of organoids to understand the impact of drug response earlier in the development process,” Jean-Charles Wirth, Merck KGaA Head of Science and Lab Solutions.